Q301--Long -Term Specialized Reference Laboratory for Measurable Residual Disease (MRD) detection in hematologic malignancies - Base Plus 4 9/1/26-8/31/31

The VA Portland Healthcare System (VHAPORHCS) Pathology & Laboratory Medicine Service Department requires continued access to specialized testing for Measurable Residual Disease (MRD) detection in hematologic malignancies. MRD is a powerful diagnostic and prognostic tool that quantifies the presence of residual cancer cells during and after treatment in patients with multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL).

• NAICS621511
• PSCQ301

• 36C26026Q0807_1.docx

  .docx14 KBNot yet available

• Hector D Gonzalez
  hector.gonzalez1@va.gov